ReviewEuropean journal of nuclear medicine and molecular imaging2016
Radium-223 dichloride in clinical practice: a review.
Review in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Preparation, Characterization, and Preliminary Imaging Study of [Contrast media & molecular imaging · 2022Article
- Single-Photon Emission Computed Tomography/Computed Tomography Image-Based Radiomics for Discriminating Vertebral Bone Metastases From Benign Bone Lesions in Patients With Tumors.Frontiers in medicine · 2021Article
- Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain.Journal of clinical medicine · 2020Review
- Article
- Targeted and Nontargeted α-Particle Therapies.Annual review of biomedical engineering · 2018Review
- Current status of theranostics in prostate cancer.European journal of nuclear medicine and molecular imaging · 2018Review
- Dosimetry-Based Consideration on Remission and Relapse after Therapy withDiagnostics (Basel, Switzerland) · 2018Article
- Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?Cancer management and research · 2018Article
- The potential ofEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.European journal of nuclear medicine and molecular imaging · 2017Article
- Radionuclide therapy of malignant bone lesions.European journal of nuclear medicine and molecular imaging · 2017Article
- Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.European journal of hybrid imaging · 2017Article
- Radium 223 dichloride for prostate cancer treatment.Drug design, development and therapy · 2017Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.